Literature DB >> 11972578

Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2.

R Uddman1, J Tajti, M Hou, F Sundler, L Edvinsson.   

Abstract

In migraine and other primary headaches there is a strong vascular component. Besides the trigeminovascular components some of the associated symptoms point to the involvement of brain stem regions. The central limb of the trigeminal vascular pathway is its projection to the trigeminal nucleus caudalis (TNC) and to the C1-C2 levels of the spinal cord. The aim of the present study was to demonstrate the occurrence of some neurotransmitters in these regions in man. In both the TNC and in the Rexed's laminae I and II of the dorsal horns at the C1 and C2 levels there were numerous substance P immunoreactive fibres. Fibres containing calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide (PACAP) were moderately dense in number. Fibres containing vasoactive intestinal peptide (VIP) or nitric oxide synthase (NOS) were not seen in the TNC or at the C1 and C2 levels of the spinal cord.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972578     DOI: 10.1046/j.1468-2982.2002.00324.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  30 in total

Review 1.  The PACAP receptor: a novel target for migraine treatment.

Authors:  Henrik W Schytz; Jes Olesen; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

2.  Current understanding of photophobia, visual networks and headaches.

Authors:  Rodrigo Noseda; David Copenhagen; Rami Burstein
Journal:  Cephalalgia       Date:  2018-06-25       Impact factor: 6.292

Review 3.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

Review 4.  Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.

Authors:  Anne Luise Haulund Vollesen; Faisal Mohammad Amin; Messoud Ashina
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 5.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

Review 6.  Photophobia in primary headaches.

Authors:  Heather L Rossi; Ana Recober
Journal:  Headache       Date:  2015-03-19       Impact factor: 5.887

Review 7.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 8.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 9.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

10.  Investigation of the immunoreactivities of NOS enzymes and the effect of sumatriptan in adolescent rats using an experimental model of migraine.

Authors:  Semra Hiz Kurul; Savas Demirpence; Müge Kiray; Kazim Tugyan; Osman Yilmaz; Galip Kose
Journal:  J Headache Pain       Date:  2008-08-08       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.